NosoGraph v2.2.0 — Public Alpha (Legacy prototype)

NosoGraph v2.2.0 — Public Alpha

NosoGraph is an open-source, evidence-native computational map of human disease designed to connect diseases and conditions to phenotypes, mechanisms, genes, variants, pathways, cells, anatomy, biomarkers, treatments, drugs, trials, literature, datasets, and computational models.

This release marks the project's public transition to NosoGraph.

Compatibility: The Python package still installs as med-research with import path med_research and CLI command med-research.

Current maturity

Public Alpha

What works today

STABLE

• Unified CLI (med-research)
• Disease validation and coverage tooling
• JSON knowledge-graph schema
• Provenance fingerprints
• Optional API-key authentication

BETA

• FastAPI web API + vanilla JavaScript dashboard
• Celery-based background jobs
• Evidence Workspace
• Universal Biomedical Store
• 40+ analysis pipelines
• Live external connectors (Open Targets, GTEx, ChEMBL, UniProt, bioRxiv)
• DuckDB-accelerated biomedical graph analytics

Disease coverage

Tier	Count	Meaning
Registry modules	10,407	MONDO-aligned slugs — mostly Open Targets auto-generated scaffolds
L2 pipeline-ready	~45	Pass strict validation (symptoms, queries, CAR-T, safety, etc.)
L3 expression-curated	23	L2 plus hand-curated GEO consensus gene lists
CI-validated (original eight)	8	sle, ra, ibd, ms, ss, ssc, t1d, ad

Important: Registry size does not equal curation depth. The 10,000+ scaffold modules are starting points for contributor curation — not validated clinical models.

Experimental

• 10,000+ Open Targets scaffolds
• Optional LLM enrichment (requires OPENAI_API_KEY)
• DuckDB graph analytics at scale

Not yet implemented

• FHIR, OMOP, Phenopackets export
• Hosted SaaS, enterprise SSO, billing
• Clinical decision support or PHI/EHR ingestion
• PyPI publish workflow

Open-source license

Apache License 2.0 for original NosoGraph software. Third-party biomedical data retains its applicable upstream licensing and attribution requirements. See docs/legal/data-licenses.md.

Next priorities

• Expand CI strict validation into the L2 disease corpus
• Reduce disease-specific CLI assumptions
• Establish canonical nosograph CLI/package compatibility
• Deepen evidence/provenance UX
• Begin the NosoGraph Compare vertical slice
• Strengthen curated disease depth
• Automate upstream biomedical-source synchronization

Important scope note

NosoGraph is a biomedical research platform. Computational outputs and research information are not a substitute for professional clinical judgment or medical diagnosis.

Full changelog: CHANGELOG.md